The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
A decade of immune-checkpoint inhibitors in cancer therapy
Open accessAbstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes (Table 1) [13].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationSafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Dejardin, D., Kraxner, A., Schindler, E., Städler, N., & Wolbers, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1351584 · Cited by 6
Musil, J., Ptacek, A., & Vaníková, Š. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24892 · Cited by 7
Peng, Y., Wang, L., Yang, J., Wu, Q., Sun, X., Zhang, J., Yu, Y., Zhang, L., Gao, J., Zhou, Q., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466779 · Cited by 7
Biomimetic nanosystems based on cell membranes (BNCMs) for cancer immunotherapy
Wang, Y., Huang, X., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.106 · Cited by 7
Zhou, C., Chen, Y., Chen, S., Hu, L., Wang, J., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1491910 · Cited by 7
Wang, Y., Ding, L., Lin, Z., Li, B., Hu, D., Zhang, S., Zhou, S., Ning, Y., Xin, F., Ying, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160294 · Cited by 8
Drevinskaitė, M., Dadonienė, J., Miltinienė, D., Patašius, A., & Smailytė, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11072039 · Cited by 7
CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
Xiao, M., Duhem, C., Chammout, A., Berchem, G., & Janji, B. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30273 · Cited by 7
Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells
Zaffran, I., Landolina, N., Gaur, P., Roviš, T. L., Jonjić, S., Mandelboim, O., Singer, B. B., & Levi‐Schaffer, F. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00486-x · Cited by 7
Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
Hamada, K., Tsunoda, T., & Yoshimura, K. (2022) · Life · doi:10.3390/life12081229 · Cited by 8
Liu, N., Wu, T., Ma, Y., Cheng, H. S., Li, W., & Chen, M. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001399 · Cited by 7
Giannotta, C., Castella, B., Tripoli, E., Grimaldi, D., Avonto, I., D’Agostino, M., Larocca, A., Kopecka, J., Grasso, M., Riganti, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1073227 · Cited by 7
Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells
Senjor, E., Ko, M.-W., Kaur, K., Chen, P.-C., Breznik, B., Chovatiya, N., Kos, J., & Jewett, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00020-3 · Cited by 7
Amylidi, A.-L., Gogadis, A., Yerolatsite, M., Zarkavelis, G., Torounidou, N., Keramisanou, V., Kampletsas, E. O., & Mauri, D. (2023) · Current Oncology · doi:10.3390/curroncol30120766 · Cited by 6
Advances in pharmacotherapeutics for hepatocellular carcinoma
Cerrito, L., Santopaolo, F., Monti, F., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892074 · Cited by 7
The impact of DNA testing on management of patients with colorectal cancer
Howe, J. R. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12526 · Cited by 6
Polyphenols as the Potential Disease-modifying Therapy in Cancer
Rogovskii, V. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220201105204 · Cited by 7
Palameta, S., Manrique-Rincón, A., Toscaro, J. M., Semionatto, I. F., Fonseca, M. D. C., Rosa, R. S. M., Ruas, L. P., de Oliveira, P. S. L., & Bajgelman, M. C. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.010 · Cited by 7
Bermas, B. L., & Zaha, V. G. (2021) · Circulation · doi:10.1161/circulationaha.120.052307 · Cited by 7
Recent Advances in Cancer Immunotherapy
Suda, K. (2021) · Biomolecules · doi:10.3390/biom11020335 · Cited by 7
Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
Foy, V., McNamara, M. G., Valle, J. W., Lamarca, Á., Edeline, J., & Hubner, R. A. (2023) · Current Oncology · doi:10.3390/curroncol30090628 · Cited by 6
Vanlaer, N., Dirven, I., Neyns, B., & Rogiers, A. (2024) · Cancers · doi:10.3390/cancers16091638 · Cited by 6
Duvall, L. E. (2024) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632241312629 · Cited by 6
Dinu, M.-D., Sima, R., Diaconescu, A.-S., Poenaru, M. O., Gorecki, G.-P., Amza, M., Popescu, M., Géorgescu, M., Constantin, A.-A., Mihai, M. M., et al. (2025) · Cancers · doi:10.3390/cancers17030389 · Cited by 6
Weichenthal, M., Ellebæk, E., Mangana, J., Asher, N., Gavrilova, I., Sekulović, L. K., Ugurel, S., Hausschild, A., Meier, F. E., Leiter, U., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115339 · Cited by 6
Self-citationYamashita, M., Yano, H., Komohara, Y., Yamada, R., Fujiwara, Y., Hirayama, M., Seki, Y., Yoshida, R., & Nakayama, H. (2025) · Microbiology and Immunology · doi:10.1111/1348-0421.13220 · Cited by 6
Approaches to overcome the current treatment plateau in immunotherapy
Giacomo, A. M. D., Canetta, R. M., Connolly, J., Leidner, R. S., Zheng, W., Kim, Y., Ibrahim, R. A., Lahn, M., Smith, M., Eggermont, A. M. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115605 · Cited by 7
Chen, J., Xin, Y., Hao, Z., Guo, H., Sun, Y., & Yang, R. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251349288 · Cited by 6
Hobson, J. N., Grams, M. P., Gicobi, J. K., Wigle, D. A., Kottschade, L. A., Durham, L. A., Corbin, K. S., Dong, H., Markovic, S. N., & Park, S. S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1697902 · Cited by 6
Jessel, M.-D., McGreevy, O., McReynolds, L., Dahal, L. N., Gilbert, T. M., Malik, H., Goldring, C. E., & Randle, L. E. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70057 · Cited by 6
Acar, C., Açar, F. P., Şahin, G., Yüksel, H. Ç., Karaca, B., & Göker, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-15460-7 · Cited by 6
Liu, R., Yu, H.-H., Li, W.-R., Wu, J.-S., Zhang, J., Luo, J., Pang, Y., Chen, Y., Yao, Y.-D., Lin, R., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.01.022 · Cited by 6
DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress
Liu, M. A. (2022) · Cancers · doi:10.3390/cancers14235874 · Cited by 6
Deciphering the Tumor–Immune–Microbe Interactions in HPV-Negative Head and Neck Cancer
Hu, M., Coleman, S. S., Fadlullah, M. Z. H., Spakowicz, D. J., Chung, C. H., & Tan, A. C. (2023) · Genes · doi:10.3390/genes14081599 · Cited by 6
Beyond the horizon: Neutrophils leading the way in the evolution of immunotherapy
Rajgopal, S., Nakano, K., & Cook, L. M. (2023) · Cancer Medicine · doi:10.1002/cam4.6761 · Cited by 5
Kareva, I., & Gevertz, J. L. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00336-6 · Cited by 6
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
Yang, S., Yang, X., Hou, Z., Zhu, L., Yao, Z., Zhang, Y., Chen, Y., Teng, J., Fang, C., Chen, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29215 · Cited by 8
Kim, G., Jarhad, D. B., Lee, G., Kim, G., Hou, X., Yu, J., Lee, C., Warnick, E., Gao, Z., Ahn, S. Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01003 · Cited by 6
Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
Xue, F., Ren, X., Kong, C., Wang, J., Liu, L., Hu, J., Shen, N., & Tang, Z. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101239 · Cited by 6
Benguerfi, S., Hirsinger, B., Raimbourg, J., Agbakou, M., Calahorro, R. M., Vennier, A., Lancrey-Javal, T., Nedelec, P., Seguin, A., Reignier, J., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08935-z · Cited by 6
Bei, W., Wang, Z., Wang, K., Shao, Z.-M., Chen, H., Xu, L., Pan, Y., Zheng, M., Geng, W., & Xu, C. (2024) · Future Oncology · doi:10.1080/14796694.2024.2421151 · Cited by 6
Chen, L., Lin, A., Luo, P., & Miao, K. (2025) · Nano Research · doi:10.26599/nr.2025.94907609 · Cited by 6
Espinos, E., Lai, R. L., & Giuriato, S. (2021) · Cells · doi:10.3390/cells10102517 · Cited by 6
Toffart, A., Feyeux, A., Pérol, M., Girard, N., Bouanani, A. E., Vignon, A., & Renault, A. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.09.014 · Cited by 6
Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
Waters, C. M. (2021) · Open Biology · doi:10.1098/rsob.210277 · Cited by 6
Moving forward in the treatment of cholangiocarcinoma
Manzia, T. M., Parente, A., Lenci, I., Sensi, B., Milana, M., Gazia, C., Signorello, A., Angelico, R., Grassi, G. B., Tisone, G., et al. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i12.1939 · Cited by 6
The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma
Fischer, S., Hamed, M., Emmert, S., Wolkenhauer, O., Fuellen, G., & Thiem, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.810058 · Cited by 7
The Role of Immune Regulatory Molecules in COVID-19
Khalifehzadeh-Esfahani, Z., Fattahi, S., Haratemeh, Z. H., & Jafarinia, M. (2022) · Viral Immunology · doi:10.1089/vim.2021.0211 · Cited by 6
Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New
Gastaldi, M., Scaranzin, S., Businaro, P., Lechiara, A., Pesce, G., Franciotta, D. M., & Lorusso, L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01279-z · Cited by 6
Shi, D., Mu, S., Pu, F., Zhong, B., Hu, B., Muhtar, M., Tong, W., Shao, Z., Zhang, Z., & Liu, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04462-4 · Cited by 6
Zhu, J.-Y., Lyu, A., Wang, Z., Chan, W., Qin, T., Miu, K.-K., & Yao, H. (2022) · Journal of Immunology Research · doi:10.1155/2022/3704798 · Cited by 6
Lee, M., Jeong, K., Park, Y. R., & Rhee, Y. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155311 · Cited by 6
Design of a protease‐activated PD‐L1 inhibitor
Goudy, O. J., Peng, A., Tripathy, A., & Kuhlman, B. A. (2023) · Protein Science · doi:10.1002/pro.4578 · Cited by 6
IL ‐7 germline variant: setting the stage for immune‐related adverse events
Issaoui, H., & Ricci, J. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13392 · Cited by 6
Orecchioni, S., Falvo, P., Talarico, G., Mitola, G., Bravetti, G., Mancuso, P., Nicoli, P., & Bertolini, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072535 · Cited by 6
Uher, O., Vanova, K. H., Lencova, R., Frejlachova, A., Wang, H., Zhuang, Z., Ženka, J., & Pacák, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1030412 · Cited by 6
Aoki, K., Nishito, Y., Motoi, N., Arai, Y., Hiraoka, N., Shibata, T., Sonobe, Y., Kayukawa, Y., Hashimoto, E., Takahashi, M., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0415 · Cited by 6
Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy
Wong, T., Fuld, A. D., & Feller-Kopman, D. J. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1769092 · Cited by 6
Putnam, C., Kondeti, L., Kesler, M. B. A., & Varney, M. E. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2022-0374 · Cited by 6
Immune checkpoint inhibitors induced side effects of the peripheral nervous system
Hundsberger, T., Schreiner, B., & Roth, P. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001188 · Cited by 6
Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
Liu, Q., Li, L., Qin, W., & Chao, T. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0281 · Cited by 6
Wusiman, D., Li, W., Guo, L., Huang, Z., Zhang, Y., Zhang, X., Zhao, X., Li, L., An, Z., Li, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22656 · Cited by 7
Mitophagy genes in ovarian cancer: a comprehensive analysis for improved immunotherapy
He, W., Chen, J., Zhou, Y., Deng, T., Feng, Y., Luo, X., Zhang, C., Huang, H., & Liu, J. (2023) · Discover Oncology · doi:10.1007/s12672-023-00750-y · Cited by 6
Pulmonary Adverse Events in Cancer Immunotherapy: Case Studies of CT Patterns
Bocchini, G., Imperato, M. C., Valente, T., Guarino, S., Lieto, R., Massimo, C., Muto, E., Romano, F., Scaglione, M., Sica, G., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14060613 · Cited by 6
Autophosphorylation and the Dynamics of the Activation of Lck
Kreußer, L. M., & Rendall, A. D. (2021) · Bulletin of Mathematical Biology · doi:10.1007/s11538-021-00900-9 · Cited by 6
CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department
Lipe, D. N., & Shafer, S. (2021) · Clinical Toxicology · doi:10.1080/15563650.2021.1880008 · Cited by 6
Patient colon and rectal operative outcomes when treated with immune checkpoint inhibitors
Calini, G., Aziz, M. A. A. E., Abdalla, S., Saeed, H. A., Lovely, J. K., D’Angelo, A.-L. D., Behm, K. T., Colibaseanu, D., Mathis, K. L., & Larson, D. W. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.03.257 · Cited by 6
Irradiation immunity interactions
Davis, D. A. S., Atmosukarto, I. I., Garrett, J., Gosling, K. M., Syed, F. M., & Quah, B. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13399 · Cited by 6
Machida, M., Yamazaki, C., Kouda, N., Hanai, Y., Sato, H., Konda, A., Yamagata, Y., Itho, T., & Aisaka, H. (2022) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-022-00261-y · Cited by 6
Dietary methionine restriction impairs anti-tumor immunity through gut microbiotaPreprint
Ji, M. H., Xu, X., Xu, Q., Xu, X., Azcárate-Peril, M. A., Wu, X., Liu, J., Locasale, J. W., Li, J., Shats, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.27.457955 · Cited by 5
Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosisPreprint
Chaudagar, K. K., Rameshbabu, S., Mei, S., Hirz, T., Hu, Y., Argulian, A., Labadie, B. W., Desai, K. B., Grimaldo, S., Kahramangil, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557996 · Cited by 6
Emerging Therapeutic Options in Pancreatic Cancer Management
Cave, D. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031929 · Cited by 5
Mastricci, A. L., Sorrentino, F., Giansiracusa, E., Zanzarelli, E., Lucia, G. S. D., Fesce, V. F., Nappi, L., & Vasciaveo, L. (2025) · Biomedicines · doi:10.3390/biomedicines13010140 · Cited by 5
Toward equitable major histocompatibility complex binding predictions
Glynn, E., Ghersi, D., & Singh, M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405106122 · Cited by 7
Chen, S., Chen, J., Kong, Y., Li, H., Chen, Z., Luo, L., Wu, Y., & Chen, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094332 · Cited by 5
Pan, Y., Zhang, B., Li, Z., & Hu, K. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101682 · Cited by 7
Sadegh, R. K., Saleki, K., & Rezaei, N. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114837 · Cited by 5
Datta, A., Bahlmann, L. C., Gong, D. N., Tevonian, E. N., Lorens, J. B., & Lauffenburger, D. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601420 · Cited by 5
Lin, S., Xiang, N., Liu, W., Wu, D., Chen, Y., Xiong, T., Ge, J., Zhou, W. H., Tian, H., Zhang, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01036 · Cited by 5
Spatial proteomics for investigating solid tumor resistance mechanisms
Zhou, X. M. M., D'Amiano, A. J., Lu, C., Madan, V., Khoshniyati, S., Kollings, J., Sunshine, N. E., Surwase, S. S., & Sunshine, J. C. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10292-0 · Cited by 5
Desai, J., Deva, S., Gao, B., Yang, K., O'Byrne, K. J., Sun, M., Liu, T., Meniawy, T. M., Yu, X., Voskoboynik, M., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04809-1 · Cited by 5
Crocetti, E., Bennett, D., Jooste, V., Rossi, S., Maso, L. D., Marcos‐Gragera, R., Smits, S., Žagar, T., Troussard, X., Mayer, A., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116061 · Cited by 5
Jiménez-Labaig, P., Mirallas, O., Martin-Quesada, A. I., Rullan, A., Trapani, D., Amaral, T. M. S., Felip, E., Tabernero, J. M., & Harrington, K. J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013072 · Cited by 5
Gajón, J. A., Juárez-Flores, Á., Mendoza-Roldan, F., Hernández-Aceves, J. A., Muñoz-Cruz, S., Pérez‐Torres, A., Fuentes‐Pananá, E. M., & Bonifaz, L. C. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2595360 · Cited by 5
Immunotherapy for Solid Tumours: Current Clinical Landscape and Future Directions
van Diepen, A. E., Kucukcelebi, S., de Vos‐Geelen, J., & Kooreman, N. G. (2025) · European Surgical Research · doi:10.1159/000549862 · Cited by 7
Pipe dream to pipeline: Journey of cancer vaccines and the road ahead
Onkar, S., Bozkus, C. C., Saxena, M., & Bhardwaj, N. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102575 · Cited by 5
Yang, X., Zhang, K., Xia, L., & Li, J. (2026) · iMetaMed · doi:10.1002/imm3.70030 · Cited by 5
Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report
Qiu, X., Ren, B., Fang, L., & Dong, Z. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12084 · Cited by 5
The Potential Role of the T2 Ribonucleases in TME-Based Cancer Therapy
Campomenosi, P., Mortara, L., Bassani, B., Valli, R., Porta, G., Bruno, A., & Acquati, F. (2023) · Biomedicines · doi:10.3390/biomedicines11082160 · Cited by 5
Fan, D., Yang, M., Lee, H. J., Lee, J. H., & Kim, H. S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1265359 · Cited by 5
Gabizón, A., Shmeeda, H., Draper, B., Parente‐Pereira, A. C., Maher, J. F., Carrascal-Miniño, A., de Rosales, R. T. M., & La-Beck, N. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112606 · Cited by 5
Abujamous, L., Soltani, A., Al-Thawadi, H., & Agouni, A. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9757 · Cited by 5
Shah, J. V., Siebert, J. N., Zhao, X., He, S., Riman, R. E., Tan, M. C., Pierce, M. C., Lattime, E. C., Ganapathy, V., & Moghe, P. V. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300092 · Cited by 5
Ding, L., Wang, F., Wang, Z., Pan, Y., Liu, T., Cheng, L., Liu, W., Ding, K., Zhu, H., & Yang, Z. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00343 · Cited by 5
A Brief Chronicle of Antibody Research and Technological Advances
Araki, K., & Maeda, R. (2024) · Antibodies · doi:10.3390/antib13040090 · Cited by 9
Rizzo, A., Monteiro, F. S. M., Mollica, V., Soares, A., Brunetti, O., Ricci, A. D., Massari, F., & Santoni, M. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10322-1 · Cited by 6
Immunotherapy‐based neoadjuvant treatment and complication rates after radical cystectomy
Ben‐David, R., Pellegrino, F., Mehrazin, R., Thomas, J., Geduldig, J. E., Lidagoster, S., Garden, E. B., Attalla, K., Eraky, A., Zaurito, P., et al. (2025) · British Journal of Urology · doi:10.1111/bju.16662 · Cited by 6
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Kim, Y., Song, J., Kim, N., & Sim, T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00881b · Cited by 6
Bei, W., Wang, Z., Xu, C., Wang, Y., Gao, H., Liu, H., Zheng, M., Jiang, Z., Zhou, Z., Liu, G., et al. (2025) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-722 · Cited by 5
Liquid biopsy for guiding breast cancer immunotherapy
Fina, E., Vitale, E., Summa, S. D., Gadaleta‐Caldarola, G., Tommasi, S., Massafra, R., Brunetti, O., & Rizzo, A. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2479426 · Cited by 5
Metadata
- Authors
- Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Corresponding author
- Robert, Caroline
- ORCID
- Robert, Caroline
- Venue
- Nature Communications
- Published
- 2020-07-30
- Volume
- 11
- Issue
- 1
- Pages
- 3801-3801
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7393098
- OpenAlex
- W3045946240
- Cited by
- 1,608
- References
- 17
- Citations by year
- 2026: 154 · 2025: 250 · 2024: 312 · 2023: 339 · 2022: 315 · 2021: 227 · 2020: 9
- FWCI
- 80.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, cancer immunotherapy, treatment efficacy assessment, immunotherapy toxicity, patient-centered care
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
